

SUPPLEMENTARY PROSPECTUS

This Supplement (the "Supplement") comprises a supplementary prospectus relating to Guaranteed Investment Products 1 PCC Limited (the "Company") prepared in accordance with the Prospectus Rules of the FSA made under Section 73A of the Financial Services and Markets Act 2000. A copy of this Supplement has been delivered to the FSA and made available to the public in accordance with the Prospectus Rules.

Each of the Directors of the Company, whose names appear in Part II of this Supplement, and the Company itself, accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Directors and the Company itself, who have taken all reasonable care to ensure that such is the case, the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information. Santander UK plc accepts responsibility for the information contained in this Supplement in so far as it relates to Santander UK plc and declares that, having taken all reasonable care to ensure that such is the case, the information contained in this Supplement in so far as it relates to Santander UK plc and for which Santander UK plc is responsible is, to the best of its knowledge, in accordance with the facts and contains no omission likely to affect its import.

GUARANTEED INVESTMENT PRODUCTS 1 PCC LIMITED

(a protected cell company incorporated with limited liability under the laws of Guernsey with registered number 42754)

This Supplement is supplementary to, and must be read in conjunction with, each of: (i) the Prospectus relating to the Protected Cell 230 Cell Shares, which comprises the Registration Document dated 22 December 2011, the Securities Note dated 27 April 2012, the Summary dated 27 April 2012, as supplemented by the Supplementary Prospectuses dated 8 May 2012, 25 May 2012 and 19 June 2012 (the "**Protected Cell 230 Prospectus**"); (ii) the Prospectus relating to the Protected Cell 231 Cell Shares, which comprises the Registration Document dated 22 December 2011, the Securities Note dated 27 April 2012, the Summary dated 27 April 2012, as supplemented by the Supplementary Prospectuses dated 8 May 2012, 25 May 2012 and 19 June 2012 (the "**Protected Cell 231 Prospectus**"); (iii) the Prospectus relating to the Protected Cell 232 Cell Shares, which comprises the Registration Document dated 22 December 2011, the Securities Note dated 22 June 2012 and the Summary dated 22 June 2012 (the "**Protected Cell 232 Prospectus**"); and (iv) the Prospectus relating to the Protected Cell 233 Cell Shares, which comprises the Registration Document dated 22 December 2011, the Securities Note dated 22 June 2012 and the Summary dated 22 June 2012 (the "**Protected Cell 233 Prospectus**", and together with the Protected Cell 230 Prospectus, the Protected Cell 231 Prospectus and the Protected Cell 232 Prospectus, the "**Prospectuses**" and each a "**Prospectus**"). Your attention is drawn, in particular, to the sections headed "Risk Factors" from page 6 of the Registration Document dated 22 December 2011 (the "**Registration Document**") forming a part of each Prospectus and from page 3 of the relevant Securities Note forming a part of each Prospectus for a discussion of certain factors that should be considered in connection with an investment in Shares. Except where the context otherwise requires, terms defined in each of the Prospectuses have the same meaning in respect of the relevant Cell when used in this document.

This document is not an offer of securities for sale in the United States. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or any securities laws of any state of the United States and may not be offered or

sold in the United States or to or for the account or benefit of US persons (as such terms are defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. The Shares will not be registered under the relevant securities laws of Canada, Australia or Japan. Accordingly, unless an exemption under such acts or laws is applicable, the Shares may not be offered, sold or delivered, directly or indirectly, in or into Canada, Australia or Japan.

9 July 2012

PART I: SIGNIFICANT NEW FACTOR

Santander UK plc Credit Rating Outlook changed by Moody's Investors Service Limited.

On 27 June 2012, Moody's Investors Service Limited (**Moody's**) changed its long-term rating outlook of Santander UK plc from Outlook Negative to Rating Under Review for possible downgrade.

1. Amendments to Protected Cell 230, 231, 232 and 233 Prospectuses:

The row relating to Moody's of the table on pages 34-35 of the Registration Document:

- (a) as deleted and replaced on page 23 of the Securities Note and further amended by the Supplementary Prospectus dated 25 May 2012, each in respect of Protected Cell 230 forming part of the Protected Cell 230 Prospectus;
- (b) as deleted and replaced on page 21 of the Securities Note and further amended by the Supplementary Prospectus dated 25 May 2012, each in respect of Protected Cell 231 forming part of the Protected Cell 231 Prospectus;
- (c) as deleted and replaced on pages 22-23 of the Securities Note in respect of Protected Cell 232 forming part of the Protected Cell 232 Prospectus; and
- (d) as deleted and replaced on pages 20-21 of the Securities Note in respect of Protected Cell 233 forming part of the Protected Cell 233 Prospectus,

is further amended as follows:

- (i) by deleting the Rating Outlook/Watch of "Negative Outlook" and replacing it with "Rating Under Review for possible downgrade"; and
- (ii) by deleting the second paragraph under the heading "Description of Rating and Rating Outlook/Watch" and replacing it in its entirety with:

"On 27 June 2012, Moody's assigned a Rating Under Review designation to the long-term rating of Santander UK plc, indicating that Santander UK plc's long-term rating is under review for possible downgrade. This overrides the outlook designation of Outlook Negative previously assigned to the long-term rating of Santander UK plc. As a result, Moody's may downgrade the long-term rating of Santander UK plc within three months of this date."

PART II: ADDITIONAL INFORMATION

1. Directors

Gavin Farrell
John Reginald Le Prevost
Steven Guy Meeks

2. Withdrawal rights

Persons who have applied for Protected Cell 230 Cell Shares, Protected Cell 231 Cell Shares, Protected Cell 232 Cell Shares and Protected Cell 233 Cell Shares prior to publication of this Supplement and who wish to exercise their statutory withdrawal rights must do so by lodging a written notice of withdrawal (which shall include a notice sent by electronic mail to Daniel.Pugh@santanderam.co.uk or by facsimile to Santander ISA Managers Limited on 0845 602 6994), which must include the full name and address of the person wishing to exercise statutory withdrawal rights and, if such person is a member of CREST, the relevant participant ID and member account ID, with Santander ISA Managers Limited, 287 St. Vincent Street, Glasgow G2 5NB so as to be received no later than two business days after the date of this Supplement (i.e. by 5.30 p.m. on 11 July 2012). Notice of withdrawal given by any other means or which is deposited with or received by Santander ISA Managers Limited after expiry of such period will not constitute a valid withdrawal.

3. Document available for inspection

Copies of this document (in addition to those listed as available for inspection at paragraph 1 of Part J of the Registration Document) may be inspected at the offices of Santander ISA Managers Limited at 287 St. Vincent Street, Glasgow G2 5NB, at the registered office of the Company during normal business hours of any business day (Saturdays, Sundays and public holidays excepted) and on the website of the Company at <http://www.anson-group.com/GIPL/GIP1PCCL.html> until the close of the relevant Offer for Subscription.

ICM:15306614.8